Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2022
Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement
4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...